Suzhou Zelgen Biopharmaceuticals Co Ltd (688266): Kapitalflussrechnung
| Preis (11.09.2026) | 52W Hoch | 52W Tief |
| 106,67 Renminbi Yuan | 160 Renminbi Yuan | 75,1 Renminbi Yuan |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| 141,075 Renminbi Yuan | - | - | - | - | - |
| #Shares | Short [%] | Short Ratio |
| 264.708.186 | - | - |
Kennzahl in 1000 CNY | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2018-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|
Umsatz | 812.733,6 | 532.954,37 | 386.438,783 | 302.305,057 | 190.360,565 | 27.660,909 | 1.311,158 | 200,334 |
Cashflow aus operativer Geschäftstätigkeit | -28.781,986 | 38.204,544 | -220.313,121 | -370.342,567 | -454.623,223 | -343.856,869 | -112.437,48 | -56.720,193 |
▸ Operative Cashflow Marge | -3,54% | 7,17% | -57,01% | -122,51% | -238,82% | -1.243,11% | -8.575,43% | -28.312,81% |
Investitionsausgaben (CapEx) | 181.466,703 | 95.690,255 | 62.601,23 | 88.623,524 | 70.738,589 | 57.680,675 | 11.081,363 | 24.319,746 |
Cashflow aus Investitionstätigkeit | - | -1.845.101,387 | 52.401,37 | -264.055,999 | 326.656,944 | -499.253,243 | -53.112,595 | -57.426,026 |
Cashflow aus Finanzierungstätigkeit | - | -51.316,415 | 1.509.365,803 | 282.791,967 | 93.993,937 | 1.899.038,872 | 285.374,625 | 124.788,657 |
Freier Cashflow | -210.248,69 | -57.485,711 | -282.914,351 | -458.966,091 | -525.361,813 | -401.537,544 | -123.518,843 | -81.039,94 |
▸ Freie Cashflow Marge | -25,87% | -10,79% | -73,21% | -151,82% | -275,98% | -1.451,64% | -9.420,59% | -40.452,41% |
Ausgeschüttete Dividenden | -26.094,318 | -24.563,574 | -21.174,721 | -11.216,268 | -4.141,157 | -1.110,688 | -1.110,688 | - |
Neuausgabe und Rückkäufe von Stammaktien | - | - | - | - | - | - | - | - |
Kennzahlen dieser Seite im Lexikon
Weitere Informationen findest du im Takani-Lexikon.